Program

John G. Gerber, MD is a Professor of Medicine and Pharmacology at the University of Colorado Health Sciences Center in the divisions of Infectious Diseases and Clinical Pharmacology. He did fellowship training in Clinical Pharmacology at Vanderbilt University School of Medicine and Infectious Diseases at the University of Colorado Health Sciences Center. He is board certified in Internal Medicine and Infectious Diseases. He recently retired from the University of Colorado Health Sciences Center after 28 years on the faculty. He presently consults for several pharmaceutical companies. While on the faculty he was an active clinician, teacher, and researcher in HIV Clinical Pharmacology. He was a productive researcher in the NIH-sponsored AIDS Clinical Trial Group since 1994, and from 2000 through 2003 he was the vice chair and then the chair of the Pharmacology Committee of ACTG. His interests in HIV therapeutics include drug-drug interactions with antiretroviral drugs, therapeutic approaches to the metabolic complications of antiretroviral therapy, therapeutic drug monitoring, and clinical trials with novel antiretroviral drugs. In addition he has performed original laboratory-based research on the chiral metabolism of methadone and antifungal azole drugs. He was the first investigator to identify CYP2B6 was the main CYP isoform involved in methadone metabolism. He has over 130 publications in peer-reviewed journals, over 50 book chapters and review articles, and has over 100 presented abstracts from various meetings. He was funded by NIH for both basic and clinical research throughout his 28 years of his career.